

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

UPDATED INFORMATION OF THE GROUP'S PRODUCTS

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that, on 4 April 2018, the amoxicillin capsule (0.25g) produced by Zhuhai United Laboratories Co., Ltd., Zhongshan branch (珠海聯邦制藥股份有限公司中山分公司), a wholly-owned subsidiary of the Company, as approved by China Food and Drug Administration, passed the consistency of quality and efficacy evaluation for generic drugs (the "Consistency Evaluation").

Amoxicillin, as a semi-synthetic penicillin antibiotic, is mainly used to treat bacterial infection and is currently one of the widely used oral antibiotics. It is a drug with the quality and efficacy consistent with that of original drugs. The Company will continue to offer high quality and trustworthy products to patients as always. The approval also lays a solid foundation for the smooth progress of the Company's other subsequent consistency evaluation projects. Benefited from the Consistency Evaluation, the Group is expected to further increase its market share in respect of semi-synthetic penicillin products among different business segments and optimise the business model of vertical integration internally, which is expected to generate positive effects on the Group's operations.

The Company will continue to proactively advance consistency of quality and efficacy evaluation for generic drugs, which is expected to create more values for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 11 April 2018

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Mr. Huang Bao Guang, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.